
浏览全部资源
扫码关注微信
1.上海中医药大学附属曙光医院(上海 201203)
2.上海市中医老年医学研究所(上海 200031)
3.中欧国际工商学院(上海 201206)
4.澎立生物医药技术(上海)股份有限公司(上海 201201)
潘昊,男,硕士研究生,主要从事神经退行性疾病研究工作
费智敏,主任医师,教授,硕士研究生导师; E-mail:tommyfei@126.com
纸质出版日期:2025-01-10,
收稿日期:2024-07-13,
移动端阅览
潘昊,刘特,张祯,等.健脾补肾方对肌萎缩侧索硬化小鼠的干预效果及作用机制[J].上海中医药杂志,2025,59(1):66-71.
PAN Hao,LIU Te,ZHANG Zhen,et al.Intervention effect and mechanism of Jianpi Bushen Formula on amyotrophic lateral sclerosis mouse[J].Shanghai Journal of Traditional Chinese Medicine,2025,59(1):66-71.
潘昊,刘特,张祯,等.健脾补肾方对肌萎缩侧索硬化小鼠的干预效果及作用机制[J].上海中医药杂志,2025,59(1):66-71. DOI: 10.16305/j.1007-1334.2025.z20240713001.
PAN Hao,LIU Te,ZHANG Zhen,et al.Intervention effect and mechanism of Jianpi Bushen Formula on amyotrophic lateral sclerosis mouse[J].Shanghai Journal of Traditional Chinese Medicine,2025,59(1):66-71. DOI: 10.16305/j.1007-1334.2025.z20240713001.
目的
2
探索健脾补肾方对肌萎缩侧索硬化(ALS)模型小鼠运动功能的影响及其机制。
方法
2
将12只采取转基因法繁育的保留部分运动功能的ADAR2flox/flox/VAChT-Cre小鼠(AR2小鼠)随机分为模型组和治疗组,每组6只;以6只同批次野生型(WT)小鼠为对照组。治疗组小鼠灌胃给予健脾补肾方[30 g/(kg·d)],对照组和模型组小鼠灌胃给予0.2 mL氯化钠溶液(9 g/L),每日1次,连续干预8周。每周观察小鼠活动状况、体质量以及抓力、抗疲劳能力(滚轮测试)等行为学功能。第24周后取样,采用苏木精-伊红(HE)染色法、尼氏染色法观察各组小鼠脊髓前角组织病理变化,采用Western blot法检测各组小鼠脊髓组织中作用于RNA的腺苷脱氨酶2(ADAR2)、转录反应DNA结合蛋白-43(TDP-43)的蛋白表达量,透射电镜观察小鼠脊髓组织超微结构。
结果
2
与对照组比较,模型组小鼠体质量随周龄逐渐增长;与模型组比较,治疗组小鼠体质量降低。与对照组比较,模型组小鼠与治疗组小鼠抗疲劳程度均有所下降,但是治疗组小鼠的抗疲劳能力下降相对模型组有所延缓。与对照组比较,模型组小鼠抓力下降;与模型组比较,治疗组抓力下降相对减缓。与对照组相比,模型组TDP-43表达量显著降低(
P
<
0.001);与模型组相比,治疗组TDP-43表达量显著升高(
P
<
0.05)。与对照组相比,模型组ADAR2表达量显著降低(
P
<
0.01),治疗组与模型组之间ADAR2表达量没有显著差异(
P
>
0.05)。与对照组相比,模型组脊髓前角运动神经元损伤严重,神经元结构不完整;与模型组相比,治疗组神经细胞凋亡数量减少。透射电镜下,模型组与对照组比较出现明显的线粒体肿胀凋亡、髓鞘脱散现象;治疗组与对照组相比较存在部分髓鞘脱散、线粒体肿胀,相对于模型组,存在肿胀凋亡现象的神经细胞数量有所减少。
结论
2
健脾补肾方能延缓ALS模型小鼠运动功能的减退,减少脊髓运动神经元的凋亡和损伤,阻止散发性ALS(sALS)病理异常标志物TDP-43的生成,保护脊髓神经元有髓神经纤维与线粒体,有效延缓ALS小鼠疾病的进展与功能的丧失。
Objective
2
To explore the effect of Jianpi Bushen Formula on motor function of amyotrophic lateral sclerosis (ALS) model mice and its mechanism.
Methods
2
Twelve ADAR2flox/flox/VAChT-Cre mice (AR2 mice) produced by transgenic method to retain part of the motor function were divided into the model group and the treatment group, with 6 mice in each group; 6 wild-type (WT) mice from the same batch were used as the control group. The mice in the treatment group were given Jianpi Bushen Formula [30 g/(kg·d)] by intragastric administration, while the mice in the control and model groups received 0.2 mL of sodium chloride solution (9 g/L) by intragastric administration once a day for 8 consecutive weeks. Mice were observed weekly for activity, body mass, and behavioral functions such as grip strength and fatigue resistance (roller test). Following a 24-week period, the mice were subjected to sampling, with the anterior horn of the spinal cord undergoing staining with both haematoxylin-eosin (HE) and Nissl stainings, in order to observe the histopathological changes in the aforementioned region of the spinal cords of the mice in all experimental groups. The protein expression of adenosine deaminase acting on RNA 2 (ADAR2) and TAR DNA-binding protein 43 (TDP-43) in the tissues of each group was detected by Western blot, and the ultrastructural changes of the anterior horn in each group were detected by transmission electron microscopy.
Results
2
In comparison to the control group, the body mass of mice in the model group exhibited a gradual increase with age, whereas the body mass in the treatment group demonstrated a decline in comparison to the model group. Compared with the control group, the anti-fatigue degree of mice in the model group and the treatment group decreased. However, the decline in anti-fatigue capacity observed in the treatment group occurred at a later stage in comparison to the model group. In comparison to the control group, the model group of mice exhibited a reduction in grip strength, with the decline in grip strength in the treatment group occurring at a relatively slower rate than that observed in the model group. The expression of TDP-43 was found to be significantly lower in the model group when contrasted with the control group (
P<
0.001). The treatment group exhibited elevated TDP-43 expression when contrasted with the model group (
P<
0.05). ADAR2 expression was observed to be significantly lower in the model group when contrasted with the control group (
P<
0.01), but no significant difference in ADAR2 expression was noted between the treatment group and the model group(
P>
0.05). Compared with the control group, the model group had severe motor neuron damage in the anterior horn of the spinal cord, and the neuronal structure was incomplete; Compared with the model group, the apoptosis number of nerve cells was reduced in the treatment group. Transmission electron microscopy revealed a notable increase in mitochondrial swelling apoptosis and demyelination in the model group when compared to the control group. Additionally, the treatment group exhibited partial demyelination and mitochondrial swelling when compared to the control group; the number of nerve cells with swelling and apoptosis was observed to be reduced when compared to the model group.
Conclusion
2
Jianpi Bushen Formula can delay the hypokinesia in ALS model mice, reduce the apoptosis and damage of spinal cord motor neurons, prevent the production of TDP-43, an abnormal marker of sporadic ALS (sALS) pathology, and protect the myelinated nerve fibers and mitochondria of spinal cord neurons, so as to effectively delay the progression of the disease and the loss of function in ALS mice.
肌萎缩侧索硬化健脾补肾方作用机制小鼠模型中药研究
amyotrophic lateral sclerosisJianpi Bushen Formulamechanism of actionmouse modeltraditional Chinese herbal medicine research
FELDMAN E L, GOUTMAN S A, PETRI S, et al. Amyotrophic lateral sclerosis[J]. Lancet, 2022, 400(10360): 1363-1380.
ILIEVA H, VULLAGANTI M, KWAN J. Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis[J]. BMJ, 2023, 383: e075037.
SCHRODER S, WANG M, SIMA D, et al. Slower progression of amyotrophic lateral sclerosis with external application of a Chinese herbal plaster-The randomized, placebo-controlled triple-blinded ALS-CHEPLA trial[J]. Front Neurol, 2022, 13: 990802.
林佳成,郑煊璐,王呈蕙,等. 基于网络药理学原理探讨健脾补肾方治疗肌萎缩侧索硬化症的机制[J]. 上海中医药大学学报,2022, 36(S1): 180-186.
GONG F, ZHU W, LIAO W, et al. Mechanism of the curative effect of Wen-Shen-Jian-Pi Prescription in the treatment of amyotrophic lateral sclerosis[J]. Front Aging Neurosci, 2022, 14: 873224.
SOPRANZI F M, FARAGALLI A, POMPILI M, et al. Incidence of amyotrophic lateral sclerosis before and during the COVID-19 pandemic: evidence from an 8-year population-based study in Central Italy based on healthcare utilization databases[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2024, 25(5-6): 554-562.
朱玮,王明哲,李婷婷,等. 健脾补肾方治疗肌萎缩侧索硬化的机制研究[J]. 神经病学与神经康复学杂志,2021, 17(2): 57-62.
潘卫东. 基于健脾疏肝补益肝肾论神经变性疾病的辨治[J]. 上海中医药大学学报,2019, 33(2): 1-6,31.
王明哲,龚帆,张静思,等. 不同临床分型与分期的肌萎缩侧索硬化症患者中医证候特征研究[J]. 上海中医药大学学报,2022, 36(2): 9-12,19.
LIN J, WANG J, WANG C, et al. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 1: Biogenic components and identification of targets and signaling pathways in amyotrophic lateral sclerosis patients[J]. Int J Clin Pharmacol Ther, 2024, 62(4): 155-161.
封宇, 王诗陶, 顾兰馨, 等. “引经导气”法针刺治疗脾胃虚弱型痿证30例[J]. 上海中医药杂志, 2020, 54(7): 73-75.
LIU Y, YAN D, YANG L, et al. Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis[J]. Transl Neurodegener, 2024, 13(1): 20.
HOSAKA T, TSUJI H, KWAK S. RNA Editing: A new therapeutic target in amyotrophic lateral sclerosis and other neurological diseases[J]. Int J Mol Sci, 2021, 22(20): 10958.
HOSAKA T, TSUJI H, TERADA M, et al. Glutamine/arginine site-unedited GluA2 mRNA in cerebrospinal fluid as a biomarker for amyotrophic lateral sclerosis[J]. J Neurol Neurosurg Psychiatry, 2023, 94(10): 876-878.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构
沪公网安备 31011502015228号